ELI LILLY AND COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
ELI LILLY AND COMPANY (LLY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$184.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-19
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$184.70M.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$79.90M.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was -$48.90M.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was -$55.70M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | -$184.70M 10-K · filed 2025-02-19 |
| 2023-12-31 | -$79.90M 10-K · filed 2025-02-19 |
| 2022-12-31 | -$48.90M 10-K · filed 2025-02-19 |
| 2021-12-31 | -$55.70M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |